UPB · Upstream Bio, Inc. · Investor Relations
$2.79
+0.04 (+1.45%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— cleared May 13, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements. The Company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these condensed consolidated financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$153.63M
Shares
54.77M
Volume · Oct 27
1.18M
Avg daily vol (3M)
817.31K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-08 | Upstream Corporate Presentation September 2026 | Presentation |
| 2026-06-10 | Goldman Sachs 47th Annual Global Healthcare Conference | Conference |
| 2026-02-11 | Phase 2 VALIANT Top-line Results in Severe Asthma | Earnings call |
| 2026-02-11 | Top-line Results for the Phase 2 VALIANT Trial in Severe Asthma | Event |
| 2025-09-02 | Phase 2 VIBRANT Top-line Results in CRSwNP | Event |
Key facts
CIK
2022626
CUSIP
91678A107
13F (30d)
12 filings
12 filers
Visit website
Investor relations